Marken Announces Depot in Russia; Makes Senior Appointment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Marken Announces Depot in Russia; Makes Senior Appointment



Marken, a provider of clinical-trial material supply solutions, has added a depot in Moscow as part of its global pharmaceutical depot network. The Russian depot will be located within an existing GxP-compliant storage facility in Moscow. The facility will be operated by staff trained on Marken’s global procedures and managed by the inventory system, Solo. It joins Marken’s current network of depots in China, Singapore, Argentina, Mexico, Germany, and the United States.

Marken’s network of pharmaceutical depot facilities and supporting IT systems are designed to provide storage and distribution of materials for clinical trials. They are designed for all clinical materials, including temperature-controlled and time-sensitive products.

In other news, Marken has appointed Michael Culme-Seymour as vice-president, Asia Pacific Region, effective Oct. 14, 2013. Culme-Seymour will be responsible for clinical logistics and Marken’s seven branches in the region, including: Singapore, Australia, India, China, Japan, Hong Kong, and Korea. Culme-Seymour has 22 years of logistics experience with airlines, express couriers, and major post companies in Singapore, Zurich, and London.  He was most recently owner of Fischer Road Express, a private company specializing in life-science logistics. 

Source: Marken

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here